Fatima Cardoso | Affiliations of authors: Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland (OP); Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (OP); Department of Oncology and Radiotherapy, Medical University of Gdask, Gdask, Poland (ES); Department of Surgery, Emory University School of Medicine, Atlanta, GA (WW); Medical Senology Research Unit, European Institute of Oncology, Milan, Italy (MC); Department of Medical Oncology, University Clinic Golnik, Golnik, Slovenia (TC); European Breast Cancer Coalition, Nicosia, Cyprus (SK); European School of Oncology, Milan, Italy (AC); Maugeri Foundation Breast Unit, Pavia, Italy (AC); Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (EPW); Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium (FC)
| 001898
| Correspondence to: Fatima Cardoso, MD, Medical Oncology & Translational Research Unit, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium (e-mail: fatima.cardoso@bordet.be).
| 001498
| E-mail: fatima.cardoso@bordet.be
| 001898
| Functional Genomics and Translational Research Unit (CS, SL, BH-K, CD), Translational Research and Medical Oncology Unit (CS, CD, DL, FC, MP), Jules Bordet Institute, Machine Learning Group (BH-K), Université Libre de Bruxelles, Brussels, Belgium; National Center of Competence in Research Molecular Oncology, Swiss Institute of Experimental Cancer Research (PW, PF, MD), Swiss Institute of Bioinformatics (PW, PF, VP, MD), CH-1066 Epalinges, Switzerland; Molecular Oncology Laboratory and Molecular Angiogenesis Laboratory, Cancer Research UK and the Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK (AH, SF); Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden (JS, JB); Department of Pathology, Uppsala University Hospital, Uppsala, Sweden (HN); Division of Diagnostic Oncology (HP, MJVdV), Division of Radiation Oncology (DN), The Netherlands Cancer Institute, Amsterdam, The Netherlands; International Drug Development Institute, Brussels, Belgium (MB)
| 000C21
| International Drug Development Institute, Brussels, Belgium (MB, MA, FP); Institut Jules Bordet, Brussels, Belgium (SL, CS, FC, MJP); Netherlands Cancer Institute, Amsterdam, The Netherlands (LvV, ER); European Institute of Oncology and University of Milan School of Medicine, Milan, Italy (GV); National Center of Competence in Research Molecular Oncology, Swiss Institute of Experimental Cancer Research, Epalinges & the Swiss Institute of Bioinformatics, Lausanne, Switzerland (MD); Agendia B.V. Amsterdam, The Netherlands (LvV, AMG, AF); Institut Gustave Roussy, Villejuif, France (MSd'A); Karolinska Institute, Stockholm, Sweden (JB); Centre René Huguenin and Institut National de la Santé et de la Recherche Médicale, St Cloud, France (RL); Guy's Hospital, London, U.K. (PE); John Radcliffe Hospital, Oxford, U.K. (AH); European Organisation for the Research and Treatment of Cancer Data Center, Brussels, Belgium (JB, PT)
| 000F08
| NONE
| 000C21 000F08 001498 001898
|
|
---|